AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04761458 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Clinical Frailty Scale
Description: The Clinical Frailty Scale (CFS) uses clinicians' judgement to evaluate frailty. It comprises assessment of specific domains including comorbidity, function, and cognition. Score ranges from 1 (very fit) to 9 (terminally ill).
Study NCT04761458 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neuropsychological test battery
Description: Patients will undergo a neuropsychological test battery preoperatively and postoperatively. This test consists of a battery of psychometric assessments with the ability to objectively assess specific cognitive domains such as attention, executive function, learning and memory, language, perceptual-motor, or social cognition.
Study NCT06107933 — intervention group
Intervention type: OTHER
Intervention: Observational only
Description: Exposure to micro and nano plastics
Study NCT05052723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib (XL184) is a potent inhibitor of multiple receptor tyrosine kinases (RTKs) known to play important roles in tumor cell proliferation and/or tumor neovascularization.
Study NCT05052723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
Study NCT05191472 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT06242821 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: Patients will continue with their current standard of care treatment.
Study NCT06242821 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: Patients will be randomized to participate in the Yoga intervention. This will consist of online 20 min yoga classes, 2 times per week. The class will be a set protocol, and patients will be given the protocol to do at home if desired.
Study NCT06634706 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: RefleXion X1 Radiotherapy System [Imaging Only]
Description: kVCT and FDG-PET imaging using the RefleXion X1 Radiotherapy System in different anatomical regions
Study NCT06634979 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective lymph node dissection
Description: For 0.5 \< CTR \< 1 and ≤ 2 cm diameter cT1N0M0 invasive non-small cell lung cancer patient sex for selective lymph node (lower mediastinal lymph nodes are not required to be cleared for upper lobe tumors and upper mediastinal lymph nodes are not required to be cleared for lower lobe tumors)
Study NCT06634472 — intervention group
Intervention type: OTHER
Intervention: AI
Description: AI-enabled skin perforator segmentation tool
Study NCT06635265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Target Stimulation (HGN, AC, GG, Strap muscles)
Description: Simulation of a combination of: HGN, AC, GG or strap muscles
Study NCT06635330 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR T cell therapy
Description: Anti-CD19 CAR-T cell therapy for R/R B-ALL pediatric patients. For patients 50 kg and less: 0.2 to 5 in ten to the power of six live CAR+ T cells per kilogram of body weight/ For patients over 50 kg: 0.1 to 2.5 in ten to the power of eight live CAR+ T cells (without considering weight).
Study NCT05700682 — intervention group
Intervention type: DEVICE
Intervention: Shoulder/Hip/Knee Embolization with Embozene Microspheres
Description: Fluoroscopically-guided arterial embolization of synovitis in the painful shoulder, hip or knee.
Study NCT06577532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABO2102
Description: mRNA encoding mutant KRAS neoantigens, administrated intramuscularly
Study NCT06577532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Anti-PD-1 antibody, administered intravenously
Study NCT06167681 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Dopaminergic Progenitor Cells
Description: Single injection of Human Dopaminergic Progenitor Cells into the putamen/striatum region of brain.
Study NCT04298541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68- DOTATATE
Description: The study intervention consists of two PET scans that will be performed using two different radiotracers, 68-Ga-DOTATATE and 68-Ga-DOTATOC. Ga-68-DOTATATE and 68-Ga-DOTATOC are PET radiotracers targeting somatostatin receptors.~The study intervention consists of 2 PET scans that will be performed at least 24h apart using 68-Ga-DOTATATE and 68-Ga-DOTATOC radiotracers, in patients with suspected meningioma that are planned for subsequent surgery.
Study NCT04298541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68-DOTATOC
Description: The study intervention consists of two PET scans that will be performed using two different radiotracers, 68-Ga-DOTATATE and 68-Ga-DOTATOC. Ga-68-DOTATATE and 68-Ga-DOTATOC are PET radiotracers targeting somatostatin receptors.~The study intervention consists of 2 PET scans that will be performed at least 24h apart using 68-Ga-DOTATATE and 68-Ga-DOTATOC radiotracers, in patients with suspected meningioma that are planned for subsequent surgery.
Study NCT04740294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Randomized to receive either magnesium sulfate or normal saline placebo.
Study NCT04740294 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium Sulfate
Description: Randomized to receive either magnesium sulfate or normal saline placebo.
Study NCT04842955 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gamma tACS (40 Hz) over the superior parietal cortex
Description: Single session of gamma tACS (40 Hz) over the superior parietal cortex
Study NCT04842955 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tACS over the superior parietal cortex
Description: Single session of sham tACS over the superior parietal cortex
Study NCT05985486 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: A reduced calorie diet which uses frozen meals purchased at the store and focuses on increasing fruits and vegetables associated with brain health.
Study NCT05985486 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Monthly health education sessions delivered remotely.
Study NCT05985486 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Monthly health education sessions delivered remotely.
Study NCT05284994 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TQ-B3525 Tablets, Osimertinib Mesylate Tablets
Description: TQ-B3525 is a novel α/δ dual inhibitor PI3K kinase inhibitor. Osimertinib mesylate is a third-generation epidermal growth factor receptor inhibitor.
Study NCT04947111 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Estimate the distribution of antibodies by serotype by Dengue virus in areas of low and high incidence of dengue
Description: Indirect IgG ELISA to estimate seroprevalence: The seropositivity will be evaluated with the Indirect IgG ELISA following the instructions of the Panbio E-DEN 01 G manufacturer, which has a specificity of 98% and a sensitivity of 100%. In brief, 10 microliters of participant serum will be used for each assay. Each kit provides a positive and negative control, as well as three calibrators, with the respective values for quality control. Samples will be classified as positive, negative or indeterminate according to the cut-off point for each ELISA kit.~Neutralizing antibody titers serotype-specific: To establish the type of humoral immunity that the selected city presents, the measurement of the neutralizing antibody titers will be carried out by means of the neutralization test by reducing the number of lytic plaques to 50% (PRNT50%) , using Vero cells and the following reference strains for each serotype: DENV-1 (HAWAI), DENV-2 (NEW GUINEA), DENV-3 (H-887) and DENV-4 (H-24)
Study NCT04838301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopregnanolone
Description: Allopregnanolone 4mg IV via 30-minute infusion, once per week.
Study NCT04838301 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline solution IV via 30-minute infusion, once per week
Study NCT05054361 — intervention group
Intervention type: PROCEDURE
Intervention: UGI Endoscopy
Description: Duodenal biopsy collection and analysis. Biopsies will be analyzed by qPCR for the expression of key epithelial molecules such as the fucosyl transferase 2 (fut2), tight junction proteins (occludin, claudin4), antimicrobial peptides (Reg3, LL37) and mucus component (mucin 2). Immune cells function will also be assessed by q-PCR for key cytokines/molecules such as IL-23, IL-17, IL-22, Foxp3, IL-10, TGFb and CVB.
Study NCT05054361 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coxsackie virus B infection status
Description: Serology against CVB and CVB specific-qPCR measurement in gut microbiota samples will be performed in all patients of the three cohorts, and analysis of the gut mucosa by qPCR and immunochemistry with anti-CVB VP1 protein mAb will be performed on a subset of patients.
Study NCT05054361 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coxsackie virus B infection status
Description: Stool samples are collected and directly kept under anaerobic condition. Within an hour the samples are processed: one fraction is aliquoted and frozen at -80°C and another fraction is used to prepared fecal supernatant for the bioassay of MAIT ligands, aliquoted and frozen. Bioassay to measure the presence of MAIT cell ligands by bioassays using WT3 cell line as well as plate bound MR117. 16S sequencing of all samples and according to the results obtained with the bioassay and 16S, 10 samples will be selected for metagenomic analysis.
Study NCT06585475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured training according to premenstrual syndrome symptom map
Description: A symptom map consisting of evidence-based practices for coping with PMS symptoms was created. An educational content based on this map was prepared and applied to women with PMS to evaluate whether it was effective compared to the control group.
Study NCT04837248 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Group 1. Conventional treatment
Description: Patients will be treated using a physiotherapy programme without digital support. A written document with exercises and recommendations will be given to them on the first day. This booklet will detail the exercises they can do depending on their surgery and the weeks elapsed, as well as the recommendations adapted according to the needs identified in the motivational interview (MI). This is the treatment that is currently being applied in the hospital.~The patient will carry out the treatment at home and will come back after 20 sessions for the corresponding assessment.
Study NCT04837248 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Group 2. Experimental treatment.
Description: A digitally supported physiotherapy programme including:~* Group session: expectations, interests, experiences with regard to their health problem and the consequences on their life, joint exercise and discussion with subsequent debate will be held.~* Exercise session: each week, patients will find different exercise videos on the platform according to the phase of recovery in which each one of them is, having been previously evaluated in the group session.~* Relaxation session: this will be carried out by means of audio that will be posted on the platform and that the patient will be able to perform simultaneously.~* Empowerment session: audio sessions that will deal with those needs that frequently arise after breast surgery in their daily lives, focusing on limiting beliefs (e.g. fear of moving), positive thoughts and information extracted from the motivational interview that should be developed.
Study NCT05221164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 162 mg
Description: Daily aspirin 162 mg during pregnancy to prevent preeclampsia
Study NCT04236557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music listening
Description: Other than usual care, subjects will listen to a 30-min individualized playlists with preferred music genres sequenced by a registered music therapist according to the ISO-Principle when agitated.
Study NCT04236557 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Audio Book Listening
Description: Other than usual care, subjects will listen to to a 30-min audio-script of book reading in Cantonese (a common dialect in Hong Kong being spoken by most people) when agitated.
Study NCT05649904 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRRAflow with Active Fluid Exchange System
Description: IRRAflow® Active Fluid Exchange System is an intracranial drainage system intended for use by professional medical hospital personnel, trained and experienced in neurosurgical medical care.~The intracranial pressure is kept at a safe level by draining excessive intracranial fluid. The system incorporates an irrigation support mechanism, used to irrigate the system in a controlled, programmed manner to minimize catheter occlusion. Additionally, a manual bolus can be given to facilitate keeping the catheter clear of occlusion or to clear the catheter of occlusion if one is present. This mechanism works by producing a bolus pulse using short periods of high flow (i.e. flow pulses).
Study NCT05649904 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: External Ventricular Drain
Description: The External Ventricular Drain (EVD) is used standard of care at the study site for ventricular drainage.
Study NCT05621720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case management
Description: On enrolment, the nurse case manager will perform the initial comprehensive assessment based on the Omaha domains of environment, psychosocial, physiological and health-related behavior. The nurse case manager will execute the intervention scheme of teaching, guidance \& counseling, treatments \& procedure, case management, and/or surveillance, with the mutual goal set with clients to promote health and self-efficacy. Home visits and telephone calls will be employed. The referral network to health and social service will be activated as appropriate.
Study NCT05621720 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Social control call and usual are
Description: Subjects in the control group will receive usual community service. in addition, a monthly social control call from trained community workers will be given to rule out the possible social effects of the intervention. These social calls will not be related the participants' health condition nor delivery of any health information.
Study NCT06516692 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Inferior Vena Cava Collapsibility/distensibility Index (IVC CI/DI) assessment
Description: Assessment of hydration status in critically ill patient recruited to this arm will be intervened through an ultrasound guided calculation of collapsibility and distensibility index of Inferior Vena Cava. This method of intervention will be continued and repeated as needed throughout the stay of the participant in intensive care unit.
Study NCT05899868 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Time to Intubation using FASTER device
Description: Time from fiberoptic placement onto airway to documentation of end-tidal carbon dioxide waveform through the endotracheal tube.
Study NCT05366556 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: The patient, whose blood will be drawn, will be asked to wear virtual reality glasses after sitting in the blood collection chair. One minute before the start of the blood collection process, Nature Hiking will be watched from the virtual reality. Meanwhile, the researcher will complete the preparations for blood collection and will start the blood collection process. It is thought that the blood collection process takes 2-3 minutes on average. During this period, virtual reality will be applied. While blood is being drawn from the patient, the researcher will assess the patient's level of pain with the VAS during the procedure. After the blood draw is completed, the virtual reality glasses will be removed. Then, the patient will be taken to the waiting area and the state anxiety scale will be applied.
Study NCT04905654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levcromakalim
Description: To investigate the role of levcromakalim compared with placebo in migraine with aura patients
Study NCT06530017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ingested, Space Occupying hydrogel capsules
Description: During the treatment period (24 weeks after enrollment), Subjects should take four (4) capsules (Ingested, Space Occupying hydrogel capsules or placebo) with water every day 10\~20 minutes before lunch and dinner, and drink at least 500ml of water
Study NCT06577376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP303c
Description: DP303c is an antibody conjugate drug (ADC), composed of one anti-HER2 monoclonal antibody coupled to one MMAE via an enzyme specific linker
Study NCT04905654 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: To investigate the role of levcromakalim compared with placebo in migraine with aura patients
Study NCT06530017 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: During the treatment period (24 weeks after enrollment), Subjects should take four (4) capsules (Ingested, Space Occupying hydrogel capsules or placebo) with water every day 10\~20 minutes before lunch and dinner, and drink at least 500ml of water
Study NCT04445805 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia (CBTI)
Description: Consists of 6 prenatal 60-min sessions and 6 monthly postnatal sessions on sleep education, sleep restriction, stimulus control, cognitive therapy, and relaxation. Treatment will be delivered via telemedicine.
Study NCT04445805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perinatal-enhanced Behavioral Therapy for Insomnia
Description: Consists of 6 prenatal 60-min sessions and 6 monthly postnatal sessions on sleep education, sleep restriction, stimulus control, and metacognitive exercises. Treatment will be delivered via telemedicine.
Study NCT04445805 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control
Description: Will include education on sleep, circadian rhythms, and good sleep hygiene in addition to self-monitoring with sleep diaries.
Study NCT04968938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midomafetamine
Description: 80 mg or 120 mg midomafetamine HCl followed by a 40 mg supplement dose
Study NCT06429098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO, once daily. Treatment in cycle 1, the dose is 100 mg on day 1, then ramp up to 400mg. In all subsequent cycles, the dose of venetoclax is initiated at 400 mg daily.
Study NCT06429098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Given SC
Study NCT06429098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV
Study NCT06429098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT04968938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Manualized therapy
Study NCT05976074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apple Watch
Description: The smartwatch will collect data including accelerometry, heart rate, activity, move time, exercise time, stand time, steps, walking and running distance, heart rate variability, respiratory rate, six-minute walk, and flights climbed. During sleep, the smartwatch will collect daily nighttime physiologic data such as time in bed, average sleep time, sleep efficiency, wake after sleep onset, nocturnal heart rate, and nocturnal respiratory rate.
Study NCT05976074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BrainRISE app
Description: The app will play a prerecorded video, which will walk participants through tasks which include holding your arms in different postures, repeating different vowel sounds and phrases as prompted, and tracing different patterns on the phone screen. The tasks are video and audio recorded while being completed. Completing the tremor assessment tasks will take about 10 minutes.
Study NCT04933578 — intervention group
Intervention type: BEHAVIORAL
Intervention: Dental anxiety scales
Description: * The Faces Version of Modified Child Dental Anxiety Scale (MCDASf), which is a psychometric dental anxiety scale for children with eight questions, was used to determine the dental anxiety levels of the children. The scores of each question are represented by varying cartoon faces according to emotions ranging from 1 'relaxed' to 5 'very anxious'. The total scores range from 8 to 40. The scores were categorized as not anxious (>9), slightly anxious (9-16), fairly anxious (17-24), very anxious (25-32), and extremely anxious (33-40).~* the Modified Dental Anxiety Scale (MDAS) was administered to parents, differently from children. The MDAS has five questions. The scores of each question range from 1 'relaxed' to 5 'very anxious.' The total score ranges from 5 to 25.
Study NCT05498376 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional pacemaker DDD
Description: Implantation of a conventional cardiac pacemaker
Study NCT05498376 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Leadless pacemaker Micra AV
Description: Implantation of a leadless cardiac pacemaker